148 related articles for article (PubMed ID: 30707493)
21. The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain.
Shirahashi H; Toriihara E; Suenaga Y; Yoshida H; Akaogi K; Endou Y; Wakabayashi M; Takashima M
Bioorg Med Chem Lett; 2019 Aug; 29(16):2320-2326. PubMed ID: 31235262
[TBL] [Abstract][Full Text] [Related]
22. Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.
Asano T; Yamazaki H; Kasahara C; Kubota H; Kontani T; Harayama Y; Ohno K; Mizuhara H; Yokomoto M; Misumi K; Kinoshita T; Ohta M; Takeuchi M
J Med Chem; 2012 Sep; 55(17):7772-85. PubMed ID: 22905713
[TBL] [Abstract][Full Text] [Related]
23. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
[TBL] [Abstract][Full Text] [Related]
24. Immunolocalization of the mitogen-activated protein kinases p42MAPK and JNK1, and their regulatory kinases MEK1 and MEK4, in adult rat central nervous system.
Flood DG; Finn JP; Walton KM; Dionne CA; Contreras PC; Miller MS; Bhat RV
J Comp Neurol; 1998 Aug; 398(3):373-92. PubMed ID: 9714150
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
26. An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.
Deng X; Zhou W; Weisberg E; Wang J; Zhang J; Sasaki T; Nelson E; Griffin JD; Jänne PA; Gray NS
Bioorg Med Chem Lett; 2012 Jul; 22(14):4579-84. PubMed ID: 22727638
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
[TBL] [Abstract][Full Text] [Related]
28. Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.
Grimster NP; Gingipalli L; Barlaam B; Su Q; Zheng X; Watson D; Wang H; Simpson I; Pike A; Balazs A; Boiko S; Ikeda TP; Impastato AC; Jones NH; Kawatkar S; Kemmitt P; Lamont S; Patel J; Read J; Sarkar U; Sha L; Tomlinson RC; Wang H; Wilson DM; Zehnder TE; Wang L; Wang P; Goldberg FW; Shao W; Fawell S; Dry H; Dowling JE; Edmondson SD
Bioorg Med Chem Lett; 2020 Oct; 30(19):127433. PubMed ID: 32717371
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Covalent MKK4/7 Dual Inhibitor.
Jiang J; Jiang B; He Z; Ficarro SB; Che J; Marto JA; Gao Y; Zhang T; Gray NS
Cell Chem Biol; 2020 Dec; 27(12):1553-1560.e8. PubMed ID: 32916088
[TBL] [Abstract][Full Text] [Related]
30. A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4.
Krishna SN; Luan CH; Mishra RK; Xu L; Scheidt KA; Anderson WF; Bergan RC
PLoS One; 2013; 8(12):e81504. PubMed ID: 24339940
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Zhu W; Chen H; Wang Y; Wang J; Peng X; Chen X; Gao Y; Li C; He Y; Ai J; Geng M; Zheng M; Liu H
J Med Chem; 2017 Jul; 60(14):6018-6035. PubMed ID: 28714692
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA
J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt.
Ko JH; Yeon SW; Ryu JS; Kim TY; Song EH; You HJ; Park RE; Ryu CK
Bioorg Med Chem Lett; 2006 Dec; 16(23):6001-5. PubMed ID: 16990001
[TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis, and Biological Evaluation of Axitinib Derivatives.
Wei N; Liang J; Peng S; Sun Q; Dai Q; Dong M
Molecules; 2018 Mar; 23(4):. PubMed ID: 29570686
[TBL] [Abstract][Full Text] [Related]
35. Cloning and characterization of microbial activated Aedes aegypti MEK4 (AaMEK4): influences of noncatalytic domains on enzymatic activity.
Wu RC; Cho WL
Insect Mol Biol; 2014 Oct; 23(5):644-55. PubMed ID: 25039995
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel Bcr-Abl
Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J
Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors.
Jiang R; Frackowiak B; Shin Y; Song X; Chen W; Lin L; Cameron MD; Duckett DR; Kamenecka TM
Bioorg Med Chem Lett; 2013 May; 23(9):2683-7. PubMed ID: 23518277
[TBL] [Abstract][Full Text] [Related]
38. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
[TBL] [Abstract][Full Text] [Related]
39. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Moschos SJ; Sullivan RJ; Hwu WJ; Ramanathan RK; Adjei AA; Fong PC; Shapira-Frommer R; Tawbi HA; Rubino J; Rush TS; Zhang D; Miselis NR; Samatar AA; Chun P; Rubin EH; Schiller J; Long BJ; Dayananth P; Carr D; Kirschmeier P; Bishop WR; Deng Y; Cooper A; Shipps GW; Moreno BH; Robert L; Ribas A; Flaherty KT
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467321
[TBL] [Abstract][Full Text] [Related]
40. Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.
Ye L; Ou X; Tian Y; Yu B; Luo Y; Feng B; Lin H; Zhang J; Wu S
Eur J Med Chem; 2013 Jul; 65():112-8. PubMed ID: 23702473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
